Johnson & Johnson said reported sales for Q3 2025 grew to $23,993 million, up 6.8%, net earnings were $5,152 million and diluted earnings per share were $2.12.

1. 01

   Johnson & Johnson said reported sales for Q3 2025 grew to $23,993 million, up 6.8%, net earnings were $5,152 million and diluted earnings per share were $2.12.

2. 02

   The company said adjusted EPS for Q3 rose to $2.80, up 15.7%, and raised the midpoint of its full-year estimated reported sales guidance to $93.7B (5.7%) from the prior guidance of $93.4B.

3. 03

   Johnson & Johnson said Innovative Medicine sales for Q3 were $15,563 million and MedTech sales were $8,430 million, each up 6.8% on a reported basis.

4. 04

   The company said it issued a separate press release (Exhibit 99.3) on October 14, 2025 announcing its intent to separate its Orthopaedics business.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.